

500


JC14 Rec'd PCT/PTO

18 JAN 2002

PATENTS

MAILING CERTIFICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on January 2, 2002


Bruce S. Londa

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty's Docket No. 101195-52

Applicant : Gerd Wallukat

Appln. Number : 09/868,967

Filed : June 22, 2001

For : Peptides and the AT₁ Receptor and Their Use for Preeclampsia and Malign Hypertension


BOX PCT
Hon. Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Notification of Defective Response mailed December 7, 2001, submitted herewith is the English translation of the drawings and the sequence listing amendment.

The Commissioner is hereby authorized to charge any fees which are required to make this response timely to deposit account no. 14-1263.

Respectfully Submitted,


Bruce S. Londa (33,531)

Attorney Applicant
Norris, McLaughlin & Marcus P.A.
220 East 42nd Street, 30th Floor
New York, N.Y. 10017
Telephone: (212)808-0700
Facsimile: (212)808-0844

PATENTS

MAIL CERTIFICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on January 2, 2002


/Bruce S. Londa

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty's Docket No.:
101195-52

APPLICANT : Gerd Wallukat

APPLN. NUMBER: 09/868,967

FILED : June 22, 2001

FOR : Peptides and the AT₁ Receptor and Their Use for
Preeclampsia and Malign Hypertension

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY,
AND/OR AMENDMENT PERTAINING THERETO
FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE

Box PCT
Hon. Assistant Commissioner of Patent
Washington, D.C. 20231

Sir:

1. This is in response to the Notification of Defective
Response mailed December 7, 2001, a copy of which is enclosed.

IDENTIFICATION OF DECLARANT

2. I, Bruce S. Londa, state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith are

- a) "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 CFR 1.821(c) and 37 CFR 1.822 and 1.823.
- b) An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 CFR 1.821(d).
- c) A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 1.821(e) and 1.824.
- d) A statement that the content of each "Sequence Listing" submitted and each computer readable copy are the same, as required in 37 CFR 1.821(g).
- e) Because this submission is made in fulfilling the requirement under 37 CFR 1.821(g), a statement that the submission includes no new matter.

STATEMENT THAT "SEQUENCE LISTING"
AND COMPUTER READABLE COPY ARE THE SAME
AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state that each computer readable form submitted in this application, including those forms requested to be

transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate. All papers accompanying this submission, or for which a request for transfer from applicant's other application, introduce no new matter.

STATUS

6. Applicant is a small entity.


AMENDMENT

7. In the specification, please add the "Sequence Listing" set forth on the attached sheets.

FEE DEFICIENCY

8. The Commissioner is hereby authorized to charge any additional fees which may be required to make this response timely, or credit any overpayment, to Deposit Account No. 14-1263.

Respectfully Submitted,



Bruce S. Londa (33,531)
Attorney for Applicant
Norris, McLaughlin & Marcus P.A.
220 East 42nd Street, 30th Floor
New York, N.Y. 10017
Telephone: (212) 808-0700
Facsimile: (212) 808-0844



UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/868,967	Gerd Wallukat	101195-52

INTERNATIONAL APPLICATION NO.	
PCT/DE99/04112	
I.A. FILING DATE	PRIORITY DATE
12/22/1999	12/24/1998

Bruce S Londa
 Norris McLaughlin & Marcus
 30th Floor
 220 East 42nd Street
 New York, NY 10017

CONFIRMATION NO. 9960

371 FORMALITIES LETTER



OC000000007163605

Date Mailed: 12/07/2001

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Indication of Small Entity Status
- Priority Document
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination
- Small Entity Statement

DATE FILED	Date: 1/7/01
Recorded by:	8622

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Translation of the application into English. The current translation of the application into English is defective as described below.
 - The text in the drawings has not been properly translated.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - This application does not contain a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an

amendment directing its entry into the specification.

- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended up to a maximum of six months.

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

FRANCINE YOUNG

Telephone: (703) 305-3662

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/868,967	PCT/DE99/04112	101195-52